← Patent-cliff monitor Loss of exclusivity March 2045 latest FDA-listed patent expiry
Drug detail Brand name SYMBRAVO Active ingredient MELOXICAM; RIZATRIPTAN BENZOATE Strength 20MG;EQ 10MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval January 2025 Marketing status RX
Listed patents Patent Expires Type 12544383 March 2045 use U-1719 12005118 January 2043 use U-1719 12611413 December 2041 use U-1719 12370196 December 2041 use U-1719 12551489 May 2040 use U-1719 12551488 May 2040 use U-1719 12128052 May 2040 use U-1719 12685736 May 2040 use U-1719 12472258 May 2038 product 12616752 May 2038 use U-4510 12472257 May 2038 use U-4134 12472256 May 2038 use U-4356 10517950 April 2036 use U-1719 11426414 April 2036 use U-1719 9821075 April 2036 product 10029010 April 2036 use U-4133 10137131 April 2036 product 10195278 April 2036 use U-1719 10695429 April 2036 use U-1719 10265324 April 2036 use U-1719 11369684 April 2036 use U-1719 10695430 April 2036 use U-1719 10363312 April 2036 use U-1719 10688185 April 2036 use U-1719 10653777 April 2036 use U-1719 10583144 April 2036 use U-1719 11331323 April 2036 use U-1719 10561664 April 2036 use U-1719 10537642 April 2036 use U-1719 10369224 April 2036 use U-4134 10532101 April 2036 use U-1719 11285213 April 2036 use U-1719 10426839 April 2036 use U-4135 10471014 April 2036 use U-1719 11219626 April 2036 use U-1719 10471069 April 2036 use U-1719 10512692 April 2036 use U-1719 11207328 April 2036 use U-1719 10512693 April 2036 use U-1719 11135295 April 2036 use U-1719 11045549 April 2036 use U-1719 11020483 April 2036 use U-1719 11826370 April 2036 use U-1719 10940153 April 2036 use U-1719 11602563 April 2036 use U-1719 11806354 April 2036 use U-1719 11510927 April 2036 use U-1719 10933137 April 2036 use U-1719 11504429 April 2036 use U-1719 11471464 April 2036 use U-1719 10933136 April 2036 use U-1719 11801250 April 2036 use U-1719 10799588 April 2036 use U-1719 10780165 April 2036 use U-1719 10821181 April 2036 use U-1719 11759522 April 2036 use U-1719 10758618 April 2036 use U-1719 10918722 April 2036 use U-1719 11738085 April 2036 use U-1719 11013805 April 2036 use U-1719 11712441 April 2036 use U-1719 10905693 April 2036 use U-1719 11628173 April 2036 use U-1719 10894053 April 2036 use U-1719 11617791 April 2036 use U-1719 10821182 April 2036 use U-1719 11617756 April 2036 use U-1719 11607456 April 2036 use U-1719 11571428 April 2036 use U-1719 11471465 April 2036 use U-1719 10780166 April 2036 use U-1719 10758617 April 2036 use U-1719 12485176 April 2036 use U-4133 10265400 April 2036 use U-4509 10265399 April 2036 use U-4509 10307484 April 2036 use U-4509 10369225 April 2036 use U-4356 11266657 April 2036 use U-1719 11433078 April 2036 use U-1719 11433079 April 2036 use U-1719 11944683 April 2036 use U-1719 12691123 April 2036 use U-1719 10058614 April 2036 product 10463736 April 2036 product 10456471 April 2036 use U-4509 10702535 April 2036 use U-4136 10702602 April 2036 use U-1719 11013806 April 2036 use U-1719 10722583 April 2036 use U-1719 10987358 April 2036 use U-1719 10729696 April 2036 use U-1719 10688102 April 2036 use U-1719 11865117 April 2036 use U-1719 10729697 April 2036 use U-1719 11617755 April 2036 use U-1719 10729773 April 2036 use U-1719
Regulatory exclusivity Code Expires NP January 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.